arrow
B

Bruno Garibaldi

a.o.u. policlinico g.rodolico-san marco
H指数:11
被引数:371

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia

更正:CPX-351在60岁以下继发急性髓系白血病患者中的真实世界多中心疗效分析

2025-12-040
OAAI
Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy

更正:连续或固定剂量卡非佐米、来那度胺和地塞米松(KRD)用于复发/难治性多发性骨髓瘤:来自欧洲骨髓瘤网络(EMN)意大利多中心回顾性真实世界调查的长期随访结果

2025-11-130
OAAI
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia

真实世界多中心分析CPX-351在60岁以下继发性急性髓系白血病患者中的疗效

2025-10-260
OA
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy

连续或固定剂量卡非佐米、来那度胺和地塞米松 (KRd) 治疗复发/难治性多发性骨髓瘤:来自欧洲骨髓瘤网络 (EMN) 意大利 多中心、回顾性真实世界研究的长-term随访

2025-10-070
OA
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study
2024-04-131
PRE
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials

接受埃罗妥珠单抗或卡非佐米联合来那度胺和地塞米松作为挽救疗法的真实复发/难治性多发性骨髓瘤患者的生存风险评分: 临床试验以外的919例分析

2022-07-184
OAAI
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials
2022-06-069
PRE
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network
2019-06-1923
OAAI